Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients

K. Kotani, Amirhossein Sahebkar, C. Serban, F. Andrica, P.P. Toth, S.R. Jones, K. Kostner, M.J. Blaha, S. Martin, J. Rysz, S. Glasser, K.K. Ray, Gerald Watts, D.P. Mikhailidis, M. Banach

Research output: Contribution to journalArticle

38 Citations (Scopus)
122 Downloads (Pure)


© 2015 Elsevier Ireland Ltd. Introduction: Circulating lipoprotein (a) (Lp(a)) is a recognized risk factor for cardiovascular disease (CVD). Tibolone, a synthetic steroid, may lower Lp(a) levels; however, evidence of the effects of tibolone on Lp(a) still remain to be defined. Therefore, we investigated the effects of tibolone treatment on circulating Lp(a) levels in postmenopausal women. Methods: The search included PUBMED, Web of Science, Scopus, and Google Scholar (up to January 31st, 2015) to identify controlled clinical studies investigating the effects of oral tibolone treatment on Lp(a) levels in postmenopausal women. Random-effects meta-regression was performed using unrestricted maximum likelihood method for the association between calculated weighted mean difference (WMD) and potential moderators. Results: Meta-analysis of data from 12 trials (16 treatment arms) suggested a significant reduction of Lp(a) levels following tibolone treatment (WMD:-25.28%, 95% confidence interval [CI]:-36.50,-14.06; p
Original languageEnglish
Pages (from-to)87-96
Issue number1
Publication statusPublished - 2015


Cite this